Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for …
Biotechnology
US, Los Altos [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
Unicycive Therapeutics, Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDUnicycive Therapeutics, Inc. can't present revenue by segment
Get PRO Today
With PRO you can bypass the blur for the segment revenues of Unicycive Therapeutics, Inc..
If you want to see a demo, head over to the financial segments of AAPL